美股新聞 標題聯播 · 近 24 小時 269 則 · 25 個來源 · 最新 9/20 07:24
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · AMGN近 30 天 22 則 · 第 1 / 1 頁
- Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks
- Amgen (AMGN) 超越大盤報酬：一些值得知道的事實Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
- What Would It Take For Eli Lilly Stock To Keep Climbing?
- AMD、Linde 與 Amgen 的頂尖研究報告Top Research Reports for AMD, Linde & Amgen
- Sotyktu 的長期乾癬性關節炎數據能提振必治妥施貴寶的前景嗎？Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
- 一款失敗的降膽固醇藥也提高了安進 (AMGN) 與禮來 (LLY) 的風險A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
- Can Volume Keep Covering Eli Lilly's Price Cuts?
- Amgen Stock Fell 10% in a Day on a Drug It Doesn’t Own. Is It Time to Buy AMGN?
- 這檔生技股為何罕見獲得雙重升評Why This Biotech Stock Just Got a Rare Double Upgrade
- ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
- 批評者警 動的災難。Anthropic ov 注相反方向。Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.
- Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
- Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
- September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio
- Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities
- 4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets
- Leading Biotech Selects Veeva Vault CRM Globally
- Is This LLY Stock Dip Big Enough To Be Worth Buying?
- Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
- Are Medical Stocks Lagging Amgen (AMGN) This Year?
- Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。